3002.15.00.11/Daratumumab (Darzalex) Injection/Canada

Daratumumab (Darzalex) Injection from Canada

Daratumumab targets CD38 for multiple myeloma. HTS 3002.15.00.11 immunological monoclonal.

Duty Rate — Canada → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Calculate with your customs valueVerify classification with AI

Import Tips

• Hematology-specific FDA paths

Daratumumab (Darzalex) Injection from Canada — Import Duty Rate | HTS 3002.15.00.11